Autologous blood derived products containing platelet-rich plasma relieve osteoarthritis symptoms on its every stage and relieve symptoms after injuries. There are numerous of clinical trials that provide evidence of safety and effectiveness of their application.

BIOVICO MEDICAL BIOTECH



Hutnicza 15 B 81-061 Gdynia, Poland, EU

+48 58 660 44 88 VAT No. PL5871662741





edica piotechnology

references

www.biovico.com



ACTION OF DKK-1 ON THE SPECIFIC SIGNALING PATHWAY.

# Blood derived products in osteoarthritis and injuries



Advanced medical biotechnology



ACTION OF DKK-1 ON THE SPECIFIC SIGNALING PATHWAY.

Autologous blood derived products containing platelet-rich plasma relieve osteoarthritis symptoms on its every stage and relieve symptoms after injuries. There are numerous of clinical trials that provide evidence of safety and effectiveness of their application.



**Effectiveness of platelet** rich plasma therapy depends on platelets amount contained in autologous plasma, because it has a direct impact on the growth factors amount in the product. Only concentration of platelet >1 million PLT/µl ensures the effectiveness of the therapy.

The highest concentration of platelets can only be obtained with specially dedicated devices. Xerthra<sup>™</sup> separation device allows on average 1.5 million PLT/µl to be obtained, what gives 8 times higher concentration than in the peripheral blood.

Biovico Sp. z o.o. Hutnicza 15 B 81-061 Gdynia, Poland, EU

+48 58 660 44 88
office@biovico.com
VAT No. PL5871662741





references

www.biovico.com